Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Rhea-AI Summary

Planet MicroCap releases a Video Interview with Cocrystal Pharma's Co-CEO and CFO, Jim Martin, discussing the company's novel antiviral therapeutics targeting various viruses. The interview highlights Cocrystal Pharma's clinical development and 2024 value catalysts.

LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses, according to the company's website (see here: https://www.cocrystalpharma.com/).

Click the following link to watch the Video Interview:

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts

You can follow Planet MicroCap on TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at: https://snn.network/terms-of-use

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Full company description and for further information about Cocrystal, please visit www.cocrystalpharma.com.

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience that are interested in learning about and to stay ahead of the curve in the MicroCap space. You can subscribe to Planet MicroCap's YouTube Channel here: https://www.youtube.com/snnwire

Planet MicroCap
info@snnwire.com

SOURCE: Planet MicroCap

View the original press release on accesswire.com

FAQ

What is the focus of Cocrystal Pharma, Inc. (COCP)?

Cocrystal Pharma focuses on discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses, and hepatitis C viruses.

Who was interviewed in the Video Interview released by Planet MicroCap?

Jim Martin, Co-CEO and CFO of Cocrystal Pharma, was interviewed in the Video Interview released by Planet MicroCap.

What viruses do Cocrystal Pharma's antiviral therapeutics target?

Cocrystal Pharma's antiviral therapeutics target influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses, and hepatitis C viruses.

Where can the Video Interview with Jim Martin be watched?

The Video Interview with Jim Martin can be watched by clicking the provided link in the press release.

What are the 2024 value catalysts discussed in the Video Interview?

The 2024 value catalysts discussed in the Video Interview include Cocrystal Pharma's clinical development progress and future growth prospects.